{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:33Z","timestamp":1789171233286,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,5]]},"DOI":"10.7759\/cureus.96156","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T20:07:30Z","timestamp":1762373250000},"source":"Crossref","is-referenced-by-count":2,"title":["Global Variability in the Management of Inflammatory Bowel Disease: Towards Context-Specific Strategies"],"prefix":"10.7759","author":[{"given":"Jeimy M","family":"Castellanos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Cooney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11938-007-0012-4","article-title":"Pharmacoeconomics and quality of life of current and emerging biologic therapies for inflammatory bowel disease","volume":"10","author":"Zisman TL","year":"2007","unstructured":"Zisman TL, Cohen RD. Pharmacoeconomics and quality of life of current and emerging biologic therapies for inflammatory bowel disease. Curr Treat Options Gastroenterol. 2007, 10:185-94. 10.1007\/s11938-007-0012-4","journal-title":"Curr Treat Options Gastroenterol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-065186","article-title":"Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019","volume":"13","author":"Wang R","year":"2023","unstructured":"Wang R, Li Z, Liu S, Zhang D. Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019. BMJ Open. 2023, 13:e065186. 10.1136\/bmjopen-2022-065186","journal-title":"BMJ Open"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29163954","article-title":"Current treatments, emerging therapeutics, and natural remedies for inflammatory bowel disease","volume":"29","author":"Yeshi K","year":"2024","unstructured":"Yeshi K, Jamtsho T, Wangchuk P. Current treatments, emerging therapeutics, and natural remedies for inflammatory bowel disease. Molecules. 2024, 29:3954. 10.3390\/molecules29163954","journal-title":"Molecules"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00360-x","article-title":"The four epidemiological stages in the global evolution of inflammatory bowel disease","volume":"18","author":"Kaplan GG","year":"2021","unstructured":"Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021, 18:56-66. 10.1038\/s41575-020-00360-x","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.02.017","article-title":"Country-level cost-effectiveness thresholds: initial estimates and the need for further research","volume":"19","author":"Woods B","year":"2016","unstructured":"Woods B, Revill P, Sculpher M, Claxton K. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016, 19:929-35. 10.1016\/j.jval.2016.02.017","journal-title":"Value Health"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.06.049","article-title":"The cost of inflammatory bowel disease care: how to make it sustainable","volume":"23","author":"Burisch J","year":"2025","unstructured":"Burisch J, Claytor J, Hernandez I, Hou JK, Kaplan GG. The cost of inflammatory bowel disease care: how to make it sustainable. Clin Gastroenterol Hepatol. 2025, 23:386-95. 10.1016\/j.cgh.2024.06.049","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2023-001225","article-title":"Biological therapy for inflammatory bowel disease: cyclical rather than lifelong treatment?","volume":"11","author":"Selinger CP","year":"2024","unstructured":"Selinger CP, Rosiou K, Lenti MV. Biological therapy for inflammatory bowel disease: cyclical rather than lifelong treatment?. BMJ Open Gastroenterol. 2024, 11:10.1136\/bmjgast-2023-001225","journal-title":"BMJ Open Gastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16445","article-title":"Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents","volume":"54","author":"van Linschoten RC","year":"2021","unstructured":"van Linschoten RC, Visser E, Niehot CD, van der Woude CJ, Hazelzet JA, van Noord D, West RL. Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents. Aliment Pharmacol Ther. 2021, 54:234-48. 10.1111\/apt.16445","journal-title":"Aliment Pharmacol Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2014-100514","article-title":"A UK cost of care model for inflammatory bowel disease","volume":"6","author":"Ghosh N","year":"2015","unstructured":"Ghosh N, Premchand P. A UK cost of care model for inflammatory bowel disease. Frontline Gastroenterol. 2015, 6:169-74. 10.1136\/flgastro-2014-100514","journal-title":"Frontline Gastroenterol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp10X482040","article-title":"NICE work: how NICE decides what we should pay for","volume":"60","author":"Stevens JW","year":"2010","unstructured":"Stevens JW. NICE work: how NICE decides what we should pay for. Br J Gen Pract. 2010, 60:7-8. 10.3399\/bjgp10X482040","journal-title":"Br J Gen Pract"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2018.0253","article-title":"Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn's disease?","volume":"31","author":"Tsui JJ","year":"2018","unstructured":"Tsui JJ, Huynh HQ. Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn's disease?. Ann Gastroenterol. 2018, 31:413-24. 10.20524\/aog.2018.0253","journal-title":"Ann Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner D","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, et al.. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021, 160:1570-83. 10.1053\/j.gastro.2020.12.031","journal-title":"Gastroenterology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00034-7","article-title":"A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial","volume":"9","author":"Noor NM","year":"2024","unstructured":"Noor NM, Lee JC, Bond S, et al.. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol. 2024, 9:415-27. 10.1016\/S2468-1253(24)00034-7","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i6.1728","article-title":"Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe","volume":"21","author":"Rencz F","year":"2015","unstructured":"Rencz F, P\u00e9ntek M, Bortlik M, et al.. Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe. World J Gastroenterol. 2015, 21:1728-37. 10.3748\/wjg.v21.i6.1728","journal-title":"World J Gastroenterol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2016.14.3.218","article-title":"Differences in the public medical insurance systems for inflammatory bowel disease treatment in Asian countries","volume":"14","author":"Wei SC","year":"2016","unstructured":"Wei SC. Differences in the public medical insurance systems for inflammatory bowel disease treatment in Asian countries. Intest Res. 2016, 14:218-23. 10.5217\/ir.2016.14.3.218","journal-title":"Intest Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.09.021","article-title":"How quickly do inflammatory bowel disease medications really work?","volume":"17","author":"Bouri S","year":"2019","unstructured":"Bouri S, Hart AL. How quickly do inflammatory bowel disease medications really work?. Clin Gastroenterol Hepatol. 2019, 17:34-5. 10.1016\/j.cgh.2018.09.021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref17","unstructured":"Crohn\u2019s & colitis UK. (2025). Accessed. August 22, 2025: https:\/\/www.crohnsandcolitis.org.uk\/info-support\/information-about-crohns-and-colitis\/all-information-about-crohns-an...."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-019-0194-3","article-title":"Drug utilization and cost associated with inflammatory bowel disease management in Saudi Arabia","volume":"17","author":"AlRuthia Y","year":"2019","unstructured":"AlRuthia Y, Alharbi O, Aljebreen AM, et al.. Drug utilization and cost associated with inflammatory bowel disease management in Saudi Arabia. Cost Eff Resour Alloc. 2019, 17:25. 10.1186\/s12962-019-0194-3","journal-title":"Cost Eff Resour Alloc"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2025.502363","article-title":"Etrasimod: review of the efficacy and therapeutic prospects of a new oral therapy for the treatment of ulcerative colitis","volume":"48","author":"Gisbert JP","year":"2025","unstructured":"Gisbert JP, Chaparro M. Etrasimod: review of the efficacy and therapeutic prospects of a new oral therapy for the treatment of ulcerative colitis. Gastroenterol Hepatol. 2025, 48:502363. 10.1016\/j.gastrohep.2025.502363","journal-title":"Gastroenterol Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-334395","article-title":"British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025","volume":"74","author":"Moran GW","year":"2025","unstructured":"Moran GW, Gordon M, Sinopolou V, et al.. British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025. Gut. 2025, 74:s1-s101. 10.1136\/gutjnl-2024-334395","journal-title":"Gut"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i5084","article-title":"Infliximab biosimilars are safe, effective, and cheap, UK audit shows","volume":"354","author":"White C","year":"2016","unstructured":"White C. Infliximab biosimilars are safe, effective, and cheap, UK audit shows. BMJ. 2016, 354:i5084. 10.1136\/bmj.i5084","journal-title":"BMJ"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"J\u00f8rgensen KK","year":"2017","unstructured":"J\u00f8rgensen KK, Olsen IC, Goll GL, et al.. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017, 389:2304-16. 10.1016\/S0140-6736(17)30068-5","journal-title":"Lancet"},{"key":"ref23","unstructured":"Guselkumab for treating moderately to severely active ulcerative colitis. (2025). Accessed. August 22, 2025: https:\/\/www.nice.org.uk\/guidance\/ta1094\/chapter\/1-Recommendations."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X251324429","article-title":"Tofacitinib in early active axial spondyloarthritis: protocol of a randomized double-blind, placebo-controlled, multicenter phase IV study, FASTLANE","volume":"17","author":"Rios Rodriguez V","year":"2025","unstructured":"Rios Rodriguez V, S\u00e1nchez-Riera L, Haibel H, et al.. Tofacitinib in early active axial spondyloarthritis: protocol of a randomized double-blind, placebo-controlled, multicenter phase IV study, FASTLANE. Ther Adv Musculoskelet Dis. 2025, 17:1759720X251324429. 10.1177\/1759720X251324429","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-08940-0","article-title":"Global evolution of inflammatory bowel disease across epidemiologic stages","volume":"642","author":"Hracs L","year":"2025","unstructured":"Hracs L, Windsor JW, Gorospe J, et al.. Global evolution of inflammatory bowel disease across epidemiologic stages. Nature. 2025, 642:458-66. 10.1038\/s41586-025-08940-0","journal-title":"Nature"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.05.032","article-title":"Gut microbiome composition is associated with future onset of Crohn\u2019s disease in healthy first-degree relatives","volume":"165","author":"Raygoza Garay JA","year":"2023","unstructured":"Raygoza Garay JA, Turpin W, Lee SH, et al.. Gut microbiome composition is associated with future onset of Crohn\u2019s disease in healthy first-degree relatives. Gastroenterology. 2023, 165:670-81. 10.1053\/j.gastro.2023.05.032","journal-title":"Gastroenterology"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.03.007","article-title":"Serum biomarkers identify patients who will develop inflammatory bowel diseases up to 5 years before diagnosis","volume":"159","author":"Torres J","year":"2020","unstructured":"Torres J, Petralia F, Sato T, et al.. Serum biomarkers identify patients who will develop inflammatory bowel diseases up to 5 years before diagnosis. Gastroenterology. 2020, 159:96-104. 10.1053\/j.gastro.2020.03.007","journal-title":"Gastroenterology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/nature14232","article-title":"Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome","volume":"519","author":"Chassaing B","year":"2015","unstructured":"Chassaing B, Koren O, Goodrich JK, Poole AC, Srinivasan S, Ley RE, Gewirtz AT. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature. 2015, 519:92-6. 10.1038\/nature14232","journal-title":"Nature"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa254","article-title":"Food additive emulsifiers and their impact on gut microbiome, permeability, and inflammation: mechanistic insights in inflammatory bowel disease","volume":"15","author":"Bancil AS","year":"2021","unstructured":"Bancil AS, Sandall AM, Rossi M, Chassaing B, Lindsay JO, Whelan K. Food additive emulsifiers and their impact on gut microbiome, permeability, and inflammation: mechanistic insights in inflammatory bowel disease. J Crohns Colitis. 2021, 15:1068-79. 10.1093\/ecco-jcc\/jjaa254","journal-title":"J Crohns Colitis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-313099","article-title":"Dietary emulsifiers directly alter human microbiota composition and gene expression ex vivo potentiating intestinal inflammation","volume":"66","author":"Chassaing B","year":"2017","unstructured":"Chassaing B, Van de Wiele T, De Bodt J, Marzorati M, Gewirtz AT. Dietary emulsifiers directly alter human microbiota composition and gene expression ex vivo potentiating intestinal inflammation. Gut. 2017, 66:1414-27. 10.1136\/gutjnl-2016-313099","journal-title":"Gut"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-020-00996-6","article-title":"Direct impact of commonly used dietary emulsifiers on human gut microbiota","volume":"9","author":"Naimi S","year":"2021","unstructured":"Naimi S, Viennois E, Gewirtz AT, Chassaing B. Direct impact of commonly used dietary emulsifiers on human gut microbiota. Microbiome. 2021, 9:66. 10.1186\/s40168-020-00996-6","journal-title":"Microbiome"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-BSG.153","article-title":"P16 Emulsifier restriction does not impair nutrient intake and improves food-related quality of life in active crohn\u2019s disease: the ADDapt trial","volume":"74","author":"Buckley A","year":"2025","unstructured":"Buckley A, Xu Y, Burke S, et al.. P16 Emulsifier restriction does not impair nutrient intake and improves food-related quality of life in active crohn\u2019s disease: the ADDapt trial. Gut. 2025, 74:100-01. 10.1136\/gutjnl-2025-BSG.153","journal-title":"Gut"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2013.06.028","article-title":"Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children","volume":"12","author":"Yang Z","year":"2014","unstructured":"Yang Z, Clark N, Park KT. Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children. Clin Gastroenterol Hepatol. 2014, 12:253-62.e2. 10.1016\/j.cgh.2013.06.028","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2015-100630","article-title":"The financial impact of a nurse-led telemedicine service for inflammatory bowel disease in a large district general hospital","volume":"7","author":"Squires SI","year":"2016","unstructured":"Squires SI, Boal AJ, Naismith GD. The financial impact of a nurse-led telemedicine service for inflammatory bowel disease in a large district general hospital. Frontline Gastroenterol. 2016, 7:216-21. 10.1136\/flgastro-2015-100630","journal-title":"Frontline Gastroenterol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2021-000745","article-title":"Review of exclusive enteral therapy in adult Crohn's disease","volume":"8","author":"Mitrev N","year":"2021","unstructured":"Mitrev N, Huang H, Hannah B, Kariyawasam VC. Review of exclusive enteral therapy in adult Crohn's disease. BMJ Open Gastroenterol. 2021, 8:000745. 10.1136\/bmjgast-2021-000745","journal-title":"BMJ Open Gastroenterol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz160","article-title":"Perioperative dietary therapy in inflammatory bowel disease","volume":"14","author":"Adamina M","year":"2020","unstructured":"Adamina M, Gerasimidis K, Sigall-Boneh R, et al.. Perioperative dietary therapy in inflammatory bowel disease. J Crohns Colitis. 2020, 14:431-44. 10.1093\/ecco-jcc\/jjz160","journal-title":"J Crohns Colitis"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12171","article-title":"High prevalence of ulcerative appendicitis in patients with ulcerative colitis","volume":"9","author":"Heuthorst L","year":"2021","unstructured":"Heuthorst L, Mookhoek A, Wildenberg ME, D'Haens GR, Bemelman WA, Buskens CJ. High prevalence of ulcerative appendicitis in patients with ulcerative colitis. United European Gastroenterol J. 2021, 9:1148-56. 10.1002\/ueg2.12171","journal-title":"United European Gastroenterol J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/417723-global-variability-in-the-management-of-inflammatory-bowel-disease-towards-context-specific-strategies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T20:07:31Z","timestamp":1762373251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/417723-global-variability-in-the-management-of-inflammatory-bowel-disease-towards-context-specific-strategies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":37,"URL":"https:\/\/doi.org\/10.7759\/cureus.96156","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,5]]}}}